Although very useful agents, fluoroquinolones are associated with a number of adverse events, some with considerable clinical significance. Prolongation of the QT interval, for example, is an adverse effect associated with the use of fluoroquinolones. Fluoroquinolones prolong the QT interval by blocking voltage-gated potassium channels, especially the rapid component of the delayed rectifier potassium current IKr, expressed by HERG (the human ether-a-go-go-related gene). According to the available case reports and clinical studies, moxifloxacin carries the greatest risk of QT prolongation from all available quinolones in clinical practice and it should be used with caution in patients with predisposing factors for Torsades de pointes (TdP). Although gemifloxacin, levofloxacin, and ofloxacin are associated with a lower risk of QT prolongation compared with moxifloxacin, they should also be used with caution in patients at risk for QT prolongation. Ciprofloxacin appears to be associated with the lowest risk for QT prolongation and the lowest TdP rate. The overall risk of TdP is small with the use of fluoroquinolones. Clinicians can minimize that risk by avoiding prescriptions of multiple medications associated with QT-interval prolongation, especially in high-risk patients.

Viskin S: Long QT syndromes and torsade de pointes: Lancet 1999;354:1625–1633.
Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B: Torsades de pointe probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350–351.
Domagala JM: Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685–706.
Kang J, Wang L, Chen XL, Triggle DJ, Rampe D: Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59:122–126.
Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S: Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine 2003;82:282–290.
Papazian DM, Schwarz TL, Tempel BL, Jan YN, Jan LY: Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science 1987;237:749–753.
Nattel S, Yue L, Wang Z: Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem 1999;9:217–226.
Snyders DJ, Tamkun MM, Bennett PB: A rapidly activating and slowly inactivating potassium channel cloned from human heart: functional analysis after stable mammalian cell culture expression. J Gen Physiol 1999;101:513–543.
Trudeau MC, Warmke JW, Ganetzky B, Robertson GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92–95.
Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R: The open pore conformation of potassium channels. Nature 2002;417:523–526.
Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC: Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003;63:1051–1058.
Shaffer D, Singer S, Korvick J, Honig P: Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197–200.
Safety pharmacology studies assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonization S7B Document. Washington, US Food and Drug Administration, 2002.
Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329–12333.
Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC: Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003;63:1051–1058.
Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, Zhou J: Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 2005;145:15–23.
January CT, Riddle JM: Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 1989;64:977–990.
Szabo B, Sweidan R, Rajagopalan CB, Lazzara R: Role of Na+:Ca2+ exchange current in Ca+-induced early afterdepolarizations in Purkinje fibers. J Cardiovasc Electrophysiol 1994;5:933–944.
Wu Y, Roden DM, Anderson ME: Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res 1999;84:906–912.
Roden DM: Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:1029–1034.
Kang J, Wang L, Chen XL, Triggle DJ, Rampe D: Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59:122–126.
Bischoff U, Schmidt C, Netzer R: Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000;406:341–343.
Lannini PB, Circiumaru I: Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy 2001;21:361–362.
Rubinstein E, Camm J: Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593–596.
Rubinstein E: Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996;37(suppl A):145–160.
Wagstaff AJ, Balfour JA: Grepafloxacin. Drugs 1997;53:817–824.
Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41–57.
Owens RC Jr: QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091–1124.
Frothingham R: Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468–1472.
Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C: Effect of a single oral dose of moxifloxacin (400 and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658–666.
Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF: Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52–56.
Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R: Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73:292–303.
Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J: Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004;44:464–473.
Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S, CAPRIE Study Group: A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs. levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128:3398–3406.
Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B: Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant ‘clinical’ event? South Med J 2006;99:52–56.
Badshah A, Janjua M, Younas F, Halabi AR, Cotant JF: Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug. Am J Med Sci 2009;338:164–166.
Dale KM, Lertsburapa K, Kluger J, White CM: Moxifloxacin and torsade de pointes. Ann Pharmacother 2007;41:336–340.
Sherazi S, DiSalle M, Daubert JP, Shah AH: Moxifloxacin-induced torsades de pointes. Cardiol J 2008;15:71–73.
Samaha FF: QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 1999;107:528–529.
Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K: Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003;60:2479–2483.
Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG: QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005;39:543–546.
Ball P, Mandell L, Patou G, Dankner W, Tillotson G: A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004;23:421–429.
Prabhakar M, Krahn AD: Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm 2004;1:624–626.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.